Sandoz

Sandoz Group AG, originally founded in 1886, has evolved into a prominent player in the healthcare sector, specializing in the development and production of high-quality generic and biosimilar medicines. The company aims to enhance patient access to affordable medications and is committed to delivering innovative solutions that meet healthcare needs worldwide. Following its spin-off from Novartis in 2023, Sandoz operates independently while continuing to uphold its legacy of quality and accessibility in pharmaceuticals. 

Sandoz is a global leader in the production and distribution of generic and biosimilar medicines, focusing on providing affordable, off-patent medications to patients worldwide, with a mission to "pioneer access for patients" by making quality medicine accessible to a large population across various therapeutic areas; they operate in over 100 countries and reach hundreds of millions of patients annually with their extensive portfolio of products. 

Key points about Sandoz:

• Focus on Generics and Biosimilars:

  Sandoz primarily develops and sells generic versions of brand-name drugs as well as biosimilars, which are highly similar versions of biologic medications. 

• Global Reach:

  With operations in over 100 countries, Sandoz provides access to affordable medications across the globe. 

• Social Impact:

  The company emphasizes its significant social impact by making medications accessible to a large patient population, contributing to healthcare cost savings. 

• Heritage:

  Sandoz has a long history in the pharmaceutical industry, previously part of Novartis before becoming a separate entity through a spin-off. 

• Purpose-Driven:

  Their core purpose is to "pioneer access for patients," meaning they prioritize making medicines available to as many people as possible.